Myelopathy associated with human T-cell lymphotropic virus type 1 in Paraguay. A case report
Main Article Content
Abstract
Myelopathy associated with HTLV-1 infection or tropical spastic paraparesis is a chronic degenerative disease of the central nervous system that mainly affects the spinal cord, it is a rare disease in our setting.
This case involves a 65-year-old woman, who presented with a 2-year history of progressive decrease in muscle strength of the lower limbs until it prevented her from walking, accompanied by urinary and fecal incontinence, and tingling in the lower limbs. Neurological physical examination: decreased muscle strength in the lower limbs (2/5), increased osteotendinous reflexes in the lower limbs, bilateral Babinky, hypoesthesia in the lateral aspect of the legs and the back and soles of the feet, patellar clonus, and no sensory level. Ancillary studies: normal cytochemical and cytological cerebrospinal. Fluid (slightly increased protein), absence of oligoclonal bands, negative HIV serology, negative autoimmune profile. Normal electromyography, normal tomography of the skull, thorax, and abdomen. Magnetic resonance imaging of the brain and spinal cord was normal at the beginning, when repeated after 8 months, inflammatory lesions in the brainand spinal cord were observed. PCR (polymerase chain reaction) in blood for HLTV-1 were positive.
The patient was treated with methylprednisolone pulses, followed by oral prednisone and azathioprine for 3 months without a favorable response and with corticosteroid side effects, so this treatment was discontinued. IV immunoglobulin 400mg kg/p/monthly for 3 months was started, with no response. Rituximab 500mg every 15 days was started 1 month ago, with the response to be evaluated in successive follow-up visits.
Conclusion: myelopathy associated with human T-cell lymphotropic virus type 1 (HTLV-1) or tropical spastic paraparesis (MAH/PET), should be considered in the differential diagnosis in a patient with myelopathy in Paraguay.
Article Details
This work is licensed under a Creative Commons Attribution 4.0 International License.
References
Acuña M, Llanos T, Jm M, Acuña JM, Llanos VT, Montaño JM. Mielopatía asociada con infección por HTLV-1: paraparesia espástica tropical Myelopathy associated with HTLV-1 infection: tropical spastic paraparesia. Acta Neurol Colomb [Internet]. 2021;37(1):40–6. doi: 10.22379/24224022323.
Enose-Akahata Y, Jacobson S. Immunovirological markers in HTLV-1-associated myelopathy/tropical spastic paraparesis (HAM/TSP). Retrovirology. [Internet] 2019. [cited 2022 Feb 22];16(1):1–14. doi: 10.1186/s12977-019-0499-5.
Matsuura E, Nozuma S, Tashiro Y, Kubota R, Izumo S, Takashima H. HTLV-1 associated myelopathy/tropical spastic paraparesis (HAM/TSP): A comparative study to identify factors that influence disease progression. J Neurol Sci [Internet]. 2016 [cited 2022 Feb 22];371:112–6. doi: 10.1016/j.jns.2016.10.030.
Quintas S, Moreno T, Lobo Antunes N, Levy Gomes A. Paraparesia espástica tropical/mielopatía asociada al HTLV-I en la infancia. Caso clínico y revisión bibliográfica. Rev neurol (Ed impr). 2004;39(12):1133–6.
Takatani M, Crispim ME, Fraiji N, Stefani MMA, Kiesslich D. Clinical and laboratory features of HTLV-I asymptomatic carriers and patients with HTLV-I-associated myelopathy/tropical spastic paraparesis from the Brazilian Amazon. Rev Inst Med Trop Sao Paulo. 2017;59:1-9. doi: 10.1590/S1678-9946201759005.
Schwalb A, Pérez-Muto V, Cachay R, Tipismana M, Álvarez C, Mejía F, et al. Early-onset HTLV-1-associated myelopathy/tropical spastic paraparesis. Pathog 2020:9:(6):450 [Internet]. 2020 [cited 2022 Feb 22]. doi: 10.3390/pathogens9060450.
Real Delor R, Moral A, Pérez L. Prevalencia de virus lifotrópico humano en dondantes de sangre del Hospital Nacional. Paraguay. Rev Médica la Paz [Internet]. 2016 [cited 2022 Feb 22]; 22(1):5-12. Disponible en: http://scielo.org.bo/scielo.php?script=sci_arttext&pid=S1726-89582016000100002.
Rodríguez-Leiva RR, Rios-González CM. Seroprevalencia de marcadores para infecciones transmisibles por transfusión en donantes de un hospital de referencia nacional de Paraguay, 2016. Mem. Inst. Investig. Cienc. Salud. 2020;18(1): 61-68. [cited 2022 Feb 22]. Disponible en: http://scielo.iics.una.py/pdf/iics/v18n1/1812-9528-iics-18-01-61.pdf
Ortiz BDM, Riveros R, Medina R, Morel M. Infective Dermatitis in an adult patient with HTLV-1. Am J Dermatopathol [Internet]. 2015 [cited 2022 Feb 22];37(12):944. doi: 10.1097/dad.0000000000000312.
Gessain A, Mahieux R. Tropical spastic paraparesis and HTLV-1 associated myelopathy: clinical, epidemiological, virological and therapeutic aspects. Rev Neurol (Paris) [Internet]. 2012 [cited 2022 Feb 22];168(3):257–69. doi: 10.1016/j.neurol.2011.12.006.
Nakamura T, Nishiura Y, Eguchi K. Therapeutic strategies in HTLV-I-associated myelopathy/tropical spastic paraparesis (HAM/TSP). Cent Nerv Syst Agents Med Chem. 2012;9(2):137–49 . doi: 10.2174/187152409788452090.
Javier F, Artal C. Immunopathogenesis and treatment of the myelopathy associated to the HTLV-I virus. 2009;48:147-155 [cited 2022 Feb 21]. doi: 10.33588/rn.4803.2008650.
Enose-Akahata Y, Billioux BJ, Azodi S, Dwyer J, Vellucci A, Ngouth N, et al. Clinical trial of raltegravir, an integrase inhibitor, in HAM/TSP. Ann Clin Transl Neurol [Internet]. 2021 [cited 2022 Feb 22];8(10):1970–85. doi: 10.1002/acn3.51437.